Company Encyclopedia
View More
name
Dyne Therapeutics
DYN.US
Dyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; facioscapulohumeral dystrophy; and Pompe disease, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. The company was incorporated in 2017 and is headquartered in Waltham, Massachusetts.
1.946 T
DYN.USMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Franklin Resources Inc. Cuts Stock Holdings in Dyne Therapeutics, Inc. $DYN

    Franklin Resources Inc. reduced its stake in Dyne Therapeutics by 1.7% in Q2, owning 0.98% of the company. Dyne's stock opened at $21.92, with a market cap of $3.13 billion. Analysts forecast growth, with a Moderate Buy rating and a $35.47 target price. CEO John Cox sold shares, decreasing his position by 1.31%. Institutional investors own 96.68% of Dyne's stock.

    Market Beat·
    US
    BEN
    +0.56%
    US
    DYN
    +2.79%
    Market Beat·
    US
    BEN
    +0.56%
    US
    DYN
    +2.79%

    Stocks To Watch: Dyne Therapeutics Sees Relative Strength Rating Rise To 93

    Dyne Therapeutics shows rising price performance, earning an upgrade to its IBD Relative Strength Rating.

    MSN·
    US
    DYN
    +2.79%
    MSN·
    US
    DYN
    +2.79%

    Oppenheimer Lowers Dyne Therapeutics (NASDAQ:DYN) Price Target to $11.00

    Oppenheimer lowered Dyne Therapeutics' price target from $13.00 to $11.00, maintaining a "market perform" rating. This suggests a potential downside of 41.76% from the current price. Other analysts have varied ratings, with some boosting targets and others issuing sell ratings. The stock's average rating is "Moderate Buy" with a consensus target price of $34.40. Dyne Therapeutics' recent earnings exceeded expectations, and institutional investors have significantly increased their stakes in the company.

    Market Beat·
    US
    DYN
    +2.79%
    Market Beat·
    US
    DYN
    +2.79%

    RBC Capital Remains a Buy on Dyne Therapeutics (DYN)

    RBC Capital's Luca Issi has maintained a Buy rating on Dyne Therapeutics (DYN) with a price target of $30.00, while the stock closed at $20.90. The analyst consensus for Dyne is Strong Buy, with a price target of $37.11, indicating a potential upside of 77.56%. LifeSci Capital also reiterated a Buy rating with a $40.00 target. Issi has an average return of 6.7% and a 41.16% success rate on his stock recommendations.

    Tip Ranks·
    US
    DYN
    +2.79%
    Tip Ranks·
    US
    DYN
    +2.79%

    Dyne Therapeutics (DYN) Gets a Buy from Stifel Nicolaus

    Stifel Nicolaus analyst Paul Matteis has maintained a Buy rating on Dyne Therapeutics (DYN) with a price target of $36.00. Matteis, a 5-star analyst, has an average return of 19.6% and a success rate of 48.82%. Additionally, Piper Sandler also reiterated a Buy rating on Dyne Therapeutics with a higher price target of $48.00 in a report released on October 27.

    Tip Ranks·
    US
    DYN
    +2.79%
    Tip Ranks·
    US
    DYN
    +2.79%
    © 2025 Longbridge｜Disclaimer